The most significant finding has been the discovery that the Ly-17 alloantigen is identical with the FcGamma2b receptor (FcR). As previous genetic evidence had inseparably linked the Ly-17 gene to the Mls locus on chromosome 1 we now postulate that FcR serves as the long-sought Mls product. Whereas a number of longstanding observations are in support of this hypothesis, the most notable experimental fact is the ability of Fc fragments to activate T helper (TH) cells. We propose to produce further evidence that Ly-17 serves as the Mls product. Ly-17 antigen will be purified and characterized biochemically. Peptide and amino acid sequence analyses will be performed. Ly-17 will be implanted via fusogenic liposomes in suitable antigen-presenting cells (APC) to test whether this maneuver will confer transient Mls stimulatory capacity. The potentially important spatial association of Ly-17 and Ia reported earlier will be re-evaluated. Finally, we will investigate the mechanism of Mls activation. Two models are suggested. The first assumes that a positive signal, emanating from Ly-17 (FcR) to an unidentified acceptor A, is enhanced in the Mls-mismatched APC-TH pair, leading in synergy with the autoreactive Ia-Ti interaction to TH activation ("heteroclicity" model). In the second model the opposite assumption is made that Ly-17 (FcR) normally imparts a dampening signal to TH. In the Mls mismatched APC-TH pair this signal may not function properly, allowing TH activation through auto-MLR ("decontrol of autoreactivity" model).
NIH ExPorter
NIH ExPorter